Neurophysiologic evaluation of long-term desferrioxamine therapy in beta-thalassemia patients

Pediatric Neurology

Volumn 18, Issue 5, 1998, Pages 420-424

  Zafeiriou, Dimitrios I ^a,b   Kousi, Afroditi A ^a   Tsantali, Chaido T ^a   Kontopoulos, Eleftherios E ^a   Augoustidou Savvopoulou, Persa A ^a   Tsoubaris, Panagiotis D ^a   Athanasiou, Miranta A ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER; DEFEROXAMINE;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; COPPER BLOOD LEVEL; DOSE RESPONSE; EVOKED AUDITORY RESPONSE; EVOKED SOMATOSENSORY RESPONSE; EVOKED VISUAL RESPONSE; EYE TOXICITY; FEMALE; HUMAN; LONG TERM CARE; MALE; NERVE CONDUCTION; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AFFERENT PATHWAYS; AGE FACTORS; BETA-THALASSEMIA; BRAIN STEM; CHILD; COPPER; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EVOKED POTENTIALS; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; EVOKED POTENTIALS, SOMATOSENSORY; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; IRON CHELATING AGENTS; LOGISTIC MODELS; MALE; NEURAL CONDUCTION; SURAL NERVE; TIME FACTORS;

EID: 0032078672     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-8994(98)00004-6     Document Type: Article

References (20)

1. Mc Donagh K, Nieuhuis A. The thalassemias. Nathan DG, Oski FA. Hematology of infancy and childhood. 4th ed. 1993;674-695 WB Saunders, Philadelphia.
2. Marsh MN, Holbrook IB, Clark C, Shaffer JL. Tinnitus in a patient with beta thalassemia on long term treatment with desferrioxamine. Postgrad Med J. 57:1981;582-584.
3. Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet. 2:1983;181-184.
4. Simon P, Ang KS, Meyrier A, Allain P, Mauras Y. Desferrioxamine, ocular toxicity and trace metals. Lancet. 2:1983;512-513.
5. Borgna-Pignatti C, De Stefano P, Broglia AM. Visual loss in patient on high dose subcutaneous desferrioxamine. Lancet. 1:1984;681.
6. Lakhahpal V, Schocket SS, Jiji R. Desferrioxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology. 91:1984;443-451.
7. Blake DR, Winyard P, Lunec J, et al. Cerebral and ocular toxicity induced by desferrioxamine. Q J Med. 56:1985;345-355.
8. Rubinstein M, Dupont P, Doppee JP, Dehon C, Ducobu J, Hainaut J. Ocular toxicity of desferrioxamine. Lancet. 1:1985;817-818.
9. Olivieri NF, Buncie JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusions. N Engl J Med. 314:1986;869-873.
10. Dickeroff R. Acute aphasia and loss of vision with DFO overdose. Am J Pediatr Hematol Oncol. 9:1987;287-288.
11. De Virgiliis S, Congia M, Turco MP, et al. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia. Arch Dis Child. 63:1988;250-255.
12. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JN. Desferrioxamine ototoxicity Evaluation of risk factors in thalassaemia patients and guideline for safe dosage . Br J Haematol. 73:1989;403-409.
13. Wonke B, Hoffbrand AV, Aldour M, et al. Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA. Arch Dis Child. 64:1989;77-82.
14. Triantafyllou N, Fisfis M, Sideris G, et al. Neurophysiological and neurootological study of homozygous beta-thalassaemia under long-term desferrioxamine (DFO) treatment. Acta Neurol Scand. 83:1991;306-308.
15. Wong V, Li A, Lee ACW. Neurophysiological study of β-thalassemia patients. J Child Neurol. 8:1993;330-335.
16. Kontzoglou G, Koussi A, Tsatra J, et al. Sensorineural hearing loss in children with thalassemia major in Northern Greece. Int J Pediatr Otorhinolaryngol. 35:1996;223-230.
17. Theodossiadis G, Ladas I, Koutsandrea C, Damanakis A, Petroutsos G. Thalassaemia and macular subretinal neovascularization. J Fr Ophthalmol. 7:1984;115-118.
18. Gartaganis S, Ismiridis K, Papageorgiou O, Beratis NG, Papanastasiou D. Ocular abnormalities in patients with β-thalassaemia. Am J Opthalmol. 108:1989;699-703.
19. Bentur Y, Koren G, Tesoro A, Carley H, Olivieri N, Freedman MH. Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity. Clin Pharmacol Ther. 47:1990;478-482.
20. Danks DM. Disorders of copper transport. Scriver CR, Beaudet AL, Sly WS, Valle D. The metabolic basis of inherited disease. 7th ed. 1995;2211-2235 McGraw-Hill, New York.